Recro Pharma Reports Second Quarter 2016 Financial Results
August 11, 2016 07:00 ET
|
Recro Pharma, Inc.
Announced Positive Top-line Results from Pivotal Phase III Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam in Abdominoplasty Ongoing with Top-line...
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
July 26, 2016 16:05 ET
|
Recro Pharma, Inc.
IV Meloxicam Achieves Primary Endpoint in First of Two Pivotal Trials Fifteen of Nineteen Secondary Endpoints Also Met Management to Host Conference Call and Webcast Today at 5:00 PM ET ...
Recro Pharma Appoints Michael Celano as Chief Financial Officer
July 05, 2016 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., July 05, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
June 02, 2016 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., June 02, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care...
Recro Pharma Reports First Quarter 2016 Financial Results
May 12, 2016 09:07 ET
|
Societal CDMO, Inc.
Enrollment on track in two pivotal Phase III IV meloxicam trials One trial expected to report top-line results by end of Q3; Other trial to report top-line results by end of Q4 Manufacturing...
Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
May 12, 2016 09:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., May 12, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious...
Recro Pharma Reports Year End 2015 Financial Results
March 24, 2016 08:19 ET
|
Societal CDMO, Inc.
MALVERN, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
Recro Pharma to Present at the 28th Annual ROTH Conference
March 07, 2016 08:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., March 07, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...
Recro Pharma Appoints Fred Graff as Chief Commercial Officer
February 16, 2016 08:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...
Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
February 01, 2016 08:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...